Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US
Shares in psychedelic drug developer Compass Pathways are sliding today after it announced that it will slash its headcount by 30% and focus all its efforts on its treatment-resistant depre
Lexeo Therapeutics' gene therapy for Alzheimer's has shown that it can reduce biomarkers of the disease in a small study, including reductions in disease biomarkers.
Eledon Pharmaceuticals has revealed that two patients with type 1 diabetes achieved a 'functional cure' after receiving a transplant of insulin-producing islet cells in combination with its
Eli Lilly says a new starting dose regimen for its Alzheimer's disease therapy Kisunla reduces the risk of side effects that have stood in the way of approvals and reimbursement decisions f
MSD and Moderna have kicked off another phase 3 trial of their personalised cancer vaccine V940 used alongside MSD's PD-1 inhibitor Keytruda, this time focusing on patients with earlier-sta
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.